6/29/23, 1:45 AM PlasmAr Study Pathway Feedback Search Clinical Topics Home Studies PlasmAr Study PlasmAr Study Disease COVID 19 infection Trial question What is the role of convalescent plasma in severe COVID-19 pneumonia? Study design Multi-center Double blinded RCT Population Characteristics of study participants 32.0% female N = 333 68.0% male 333 patients (108 female, 225 male) Inclusion criteria: hospitalized adult patients with severe COVID-19 pneumonia Key exclusion criteria: pregnancy or lactation, a history of blood component allergies, an infectious cause of pneumonia other than Coronavirus 2019, a requirement for mechanical ventilation, multiorgan failure Interventions N=228 convalescent plasma (a single administration of a median titer of 1:3200 of total Coronavirus 2019 antibodies plus standard treatment) N=105 placebo (normal saline solution plus standard treatment) Primary outcome https://web.pathway.md/studies/recTRahzRHsoBxA1o 1/2 6/29/23, 1:45 AM PlasmAr Study Pathway Death at 30 days 11.4 % 11.43 10.96 8.6 % 5.7 % 2.9 % No significant difference 0.0 % Convalescent plasma Placebo No significant difference in death at 30 days (10.96% vs. 11.43%; ARD -0.46, 95% CI -7.8 to 6.8) Secondary outcomes No significant difference in median time from intervention to hospital discharge (13 days vs. 12 days; subHR 0.99, 99% CI 0.75 to 1.32) Safety outcomes No significant difference in overall adverse events and serious adverse events. Significant difference in infusion-related adverse events (4.8% vs. 1.9%) and nonhemolytic febrile reactions (2.2% vs. 0%). Conclusion In hospitalized adult patients with severe COVID-19 pneumonia, convalescent plasma was not superior to placebo with respect to death at 30 days. Reference Ventura A Simonovich, Leandro D Burgos Pratx, Paula Scibona et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619-629. Open reference URL https://web.pathway.md/studies/recTRahzRHsoBxA1o 2/2